Legal & General Group’s scPharmaceuticals SCPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-4,571
| Closed | -$25.9K | – | 3431 |
|
|
2025
Q3 | $25.9K | Buy |
4,571
+710
| +18% | +$3.64K | ﹤0.01% | 2936 |
|
|
2025
Q2 | $14.7K | Sell |
3,861
-564
| -13% | -$1.75K | ﹤0.01% | 3136 |
|
|
2025
Q1 | $11.6K | Hold |
4,425
| – | – | ﹤0.01% | 3124 |
|
|
2024
Q4 | $15.7K | Buy |
4,425
+1,406
| +47% | +$5.38K | ﹤0.01% | 3115 |
|
|
2024
Q3 | $13.8K | Hold |
3,019
| – | – | ﹤0.01% | 3189 |
|
|
2024
Q2 | $13.1K | Hold |
3,019
| – | – | ﹤0.01% | 3207 |
|
|
2024
Q1 | $15.2K | Hold |
3,019
| – | – | ﹤0.01% | 3083 |
|
|
2023
Q4 | $18.9K | Hold |
3,019
| – | – | ﹤0.01% | 3052 |
|
|
2023
Q3 | $21.5K | Sell |
3,019
-467
| -13% | -$3.68K | ﹤0.01% | 2995 |
|
|
2023
Q2 | $35.5K | Buy |
+3,486
| New | +$36.4K | ﹤0.01% | 2920 |
|
|
2021
Q2 | – | Sell |
-827
| Closed | -$6K | – | 3629 |
|
|
2021
Q1 | $6K | Hold |
827
| – | – | ﹤0.01% | 3463 |
|
|
2020
Q4 | $4K | Hold |
827
| – | – | ﹤0.01% | 3445 |
|
|
2020
Q3 | $6K | Sell |
827
-52
| -6% | -$406 | ﹤0.01% | 3366 |
|
|
2020
Q2 | $6K | Buy |
+879
| New | +$7.72K | ﹤0.01% | 3373 |
|
|
2019
Q3 | – | Sell |
-1,265
| Closed | -$4K | – | 3402 |
|
|
2019
Q2 | $4K | Hold |
1,265
| – | – | ﹤0.01% | 3460 |
|
|
2019
Q1 | $4K | Hold |
1,265
| – | – | ﹤0.01% | 3322 |
|
|
2018
Q4 | $5K | Hold |
1,265
| – | – | ﹤0.01% | 3337 |
|
|
2018
Q3 | $7K | Hold |
1,265
| – | – | ﹤0.01% | 3356 |
|
|
2018
Q2 | $7K | Hold |
1,265
| – | – | ﹤0.01% | 3324 |
|
|
2018
Q1 | $16K | Buy |
+1,265
| New | +$17K | ﹤0.01% | 3148 |
|
Legal & General Group's SCPH Position: Q4 2025 in Review
Legal & General Group sold out of scPharmaceuticals (SCPH) in Q4 2025, closing a stake of 4,571 shares — an estimated $25.9K sold.
Legal & General Group first reported a position in SCPH in Q1 2018 and held it in 20 quarters. The position peaked at $35.5K in Q2 2023. 0 funds tracked by Wall St. Rank hold SCPH as of Q4 2025.
- Legal & General Group reported no remaining scPharmaceuticals position as of Q4 2025 after selling out during the quarter.
- Legal & General Group sold 4,571 scPharmaceuticals shares in Q4 2025, an estimated $25.9K.
- Legal & General Group first reported a position in scPharmaceuticals in Q1 2018 and held it in 20 quarters.
- Legal & General Group's scPharmaceuticals position peaked at $35.5K in Q2 2023.
- 0 funds tracked by Wall St. Rank held scPharmaceuticals as of Q4 2025.
Based on Legal & General Group's 13F filing for Q4 2025, filed 9 Feb 2026.